Open Orphan Plc
ORPH.LN
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and has offices in London, Dublin, Paris, and the Netherlands. Open Orphan is led by a management team with deep industry and financial experience.
Related content
Press Releases
|
Open Orphan announces second deal in a week – hear more on the ValueTheMarkets podcast (ORPH)
Investing Ideas
|
ValueTheMarkets Podcast 030 - with Cathal Friel, CEO of Open Orphan (ORPH)
News
|
Open Orphan signs key agreement with major biopharma player (ORPH)
Investing Ideas
|
VIDEO: Open Orphan’s Maurice Treacy details pharma services firm’s ambitious growth plans in exclusive ValueTheMarkets presentation (ORPH)
Investing Ideas
|
EXCLUSIVE WEBINAR: Open Orphan to discuss its ambitious plans for high growth in the pharma services market (ORPH)
Investing Ideas
|
Open Orphan – Consolidating the fragmented pharma services market (ORPH)
Sign up for VTM Updates
Top Picks for Q2 2022
View MoreCrypto Corner
Learn your NFTs from your BTCs